Home Featured Page 13

Featured

Latest

Did New Jersey Really Just Legalize Psilocybin?

Psychedelic Funding, Public Markets, and M&A in 2025

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

The Psychedelic News Feed: January 5 – June 1, 2025

Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in...

Mareesa Stertz & Tania Abdul – Sphinx Gate: Know Thyself at...

Psilocybin Enters German Psychiatry: A Clinical Milestone for Mental Health

Alan Davis – Psychedelic Research and Patient Safety at Ohio State...

Chad Charles – Integrating 5-MeO-DMT: Therapy, Harm Reduction, and Best Practices

Germany Establishes EU’s First Psilocybin Compassionate Access Program

Chad Charles – Integrating 5-MeO-DMT: Therapy, Harm Reduction, and Best Practices

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness,...

William Leonard Pickard interviews Bryan Hubbard about the new policy frontier...

1...121314...306 Page 13 of 306

Did New Jersey Really Just Legalize Psilocybin?

Psychedelic Funding, Public Markets, and M&A in 2025

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Did New Jersey Really Just Legalize Psilocybin?

Psychedelic Funding, Public Markets, and M&A in 2025

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

The Psychedelic News Feed: January 5 – June 1, 2025

Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in...

Mareesa Stertz & Tania Abdul – Sphinx Gate: Know Thyself at...

Psilocybin Enters German Psychiatry: A Clinical Milestone for Mental Health

Alan Davis – Psychedelic Research and Patient Safety at Ohio State...

Chad Charles – Integrating 5-MeO-DMT: Therapy, Harm Reduction, and Best Practices

Germany Establishes EU’s First Psilocybin Compassionate Access Program

Chad Charles – Integrating 5-MeO-DMT: Therapy, Harm Reduction, and Best Practices

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness,...

William Leonard Pickard interviews Bryan Hubbard about the new policy frontier...

EDITOR PICKS

Did New Jersey Really Just Legalize Psilocybin?

Psychedelic Funding, Public Markets, and M&A in 2025

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY